部份中文硫酸卡那霉素处方资料（仅供参考）
药品英文名
Kanamycin
药品别名
康纳、康丝菌素、Kanamycinum、Anamid、Kanacine、Kamynex、Kanabiot、Kanacetic、Kanamytrex、Kanasyn、Kantrex
药理作用
卡那霉素是一种氨基糖苷类药。其抗菌作用机制与链霉素相同，通过作用于细菌体内的核糖体，抑制细菌蛋白质合成，并破坏细菌细胞膜的完整性。卡那霉素对革兰阴性杆菌如大肠杆菌、变形杆菌属、产气杆菌、肺炎克雷白菌、黏质沙雷菌等具有较强抗菌活性。本药对革兰阳性菌(金黄色葡萄菌除外)、铜绿假单胞菌、厌氧菌、非典型性分枝杆菌、立克次体、真菌等无效。
药动学
卡那霉素口服不易吸收，肌内注射后吸收迅速，局部冲洗或局部给药后也有一定量的药物从皮肤表面吸收。肌内注射0.5g后，血药浓度于1～2h达峰值，约为20μg/ml，胆汁中浓度在肌注后约6h达峰值。一次给药7.5mg/kg后平均血药峰浓度为22μg/ml。本药分布容积约为0.26L/kg。药物吸收后主要分布于细胞外液，其中5%～15%可再分布到组织中。药物在肾皮质细胞中蓄积，尿液中药物浓度较高；支气管分泌物、脑脊液、蛛网膜下腔、眼组织以及房水中浓度较低。本药可透过胎盘屏障，在脐带血中达到的药物浓度与母体中血药浓度相近。正常婴儿脑脊液中浓度可达同期血药浓度的10%～20%，当脑膜有炎症时，可达同期血药浓度的50%。本药血浆蛋白结合率低。药物在体内不代谢，主要经肾小球滤过随尿液排泄。给药后4h内排出约50%，24h内排出约80%～90%，尿中浓度可高达血药浓度的10～20倍。另有少量药物从胆汁(约1%)、乳汁中排出。健康成人半衰期为2～4h；肾功能损害者为27～80h，足月新生儿为6～8.6h，早产儿为18h。药物可经血液透析和腹膜透析清除。
适应证
1.用于治疗敏感菌所致的系统感染，如肺炎、败血症、尿路感染等。
2.用于治疗敏感菌所致的肠道感染及用作肠道手术前准备。
3.用于防止肝硬化消化道出血患者发生肝性脑病(有减少肠道细菌产生氨的作用)。
4.局部给药用于治疗敏感菌所致结膜炎、角膜炎、泪囊炎、眼睑炎、睑板腺炎等。 
用法用量
1.成人:(1)口服给药：
①用于防止肝性脑病:每天4g，分次给予。
②手术前准备:每小时1g，连续4次(常与甲硝唑联合应用)。
(2)肌内注射：每次0.5g，每天1.0g(按卡那霉素计，下同)。或5～7.5mg/kg，每8～12小时1次。每天用量不超过1.5g，疗程7～14天。
(3)静脉滴注：每次0.5g，每天1.0g，或5～7.5mg/kg，每8～12小时1次。每天用量不超过1.5g，疗程7～14天。
2.儿童:
(1)肌内注射：每天15～25mg/kg，分2次给药。
(2)静脉滴注：每天15～25mg/kg，分2次给药。
药物相应作用
参见：链霉素
注：本品美国上市
包装规格
3毫升小瓶 1克/3毫升（333毫克/毫升）
3毫升小瓶 1克/3毫升（333毫克/毫升）*10小瓶/盒

生产商：
SPL UNCLASSIFIED SECTION
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Kanamycin Injection, USP and other antibacterial drugs, Kanamycin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
DESCRIPTION
Kanamycin sulfate is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus.  It is D-Streptamine, 0-3-amino-3-deoxy-α-D-glucopyranosyl - (1→6)-0- [6-amino-6-deoxy-α-D-glucopyranosyl - (1→4)]-2-deoxy, sulfate 1:1 (salt).  It consists of two amino sugars glycosidically linked to deoxystreptamine.

Kanamycin Injection, USP, sterile solution for parenteral administration, contains respectively; kanamycin sulfate equivalent to 500 mg and 1g kanamycin; sodium bisulfite, an antioxidant, 0.66% and 0.45%; and sodium citrate, 2.2% and 2.2% with pH of each dosage form adjusted to 4.5 with sulfuric acid.
CLINICAL PHARMACOLOGY
The drug is rapidly absorbed after intramuscular injection and peak serum levels are generally reached within approximately one hour.  Doses of 7.5 mg/kg give mean peak levels of 22 mcg/mL.  At 8 hours following a 7.5 mg/kg dose, mean serum levels are 3.2 mcg/mL.  The serum half-life is 2 1/2 hours.  Intravenous administration of kanamycin over a period of one hour resulted in serum concentrations similar to those obtained by intramuscular administration.
Kanamycin diffuses rapidly into most body fluids including synovial and peritoneal fluids and bile.  Significant levels of the drug appear in cord blood and amniotic fluid following intramuscular administration to pregnant patients.  Spinal fluid concentrations in normal infants are approximately 10 to 20 percent of serum levels and may reach 50 percent when the meninges are inflamed.
Studies in normal adult patients have shown only trace levels of kanamycin in spinal fluid.  No data are available on adults with meningitis.
The drug is excreted almost entirely by glomerular filtration and is not reabsorbed by the renal tubules.  Hence, high concentrations are attained in the nephron, and the urine may contain levels 10 to 20 times higher than those in serum.  Little, if any, metabolic transformation occurs.  Renal excretion is extremely rapid.  In patients with normal renal function, approximately one-half of the administered dose is cleared within 4 hours and excretion is complete within 24 to 48 hours.  Patients with impaired renal function or with diminished glomerular filtration pressure excrete kanamycin more slowly.  Such patients may build up excessively high blood levels which greatly increase the risk of ototoxic reactions.  In severely burned patients the half-life may be significantly decreased and resulting serum concentrations may be lower than anticipated from the mg per kg dose.
MicrobiologyKanamycin is a bactericidal antibiotic which acts by inhibiting the synthesis of protein in susceptible microorganisms.  Kanamycin sulfate is active in vitro against many strains of Staphylococcus aureus (including penicillinase and non penicillinase-producing strains), Staphylococcus epidermidis, N. gonorrhoeae, H. influenzae, E. coli, Enterobactor aerogenes, Shigella and Salmonella species, K. pneumoniae, Serratia marcescens, Providencia species, Acinetobacter species and Citrobacter freundii and Citrobacter species, and many strains of both indole-positive and indole-negative Proteus strains that are frequently resistant to other antibiotics.
Aminoglycosides have a low order of activity against most gram-positive organisms including Streptococcus pyogenes, Streptococcus pneumoniae and enterococci.  In vitro studies have demonstrated that an aminoglycoside combined with an antibiotic which interferes with cell wall synthesis (i.e., Penicillin G or ampicillin) affects some Group D streptococcal strains synergistically.  Bacteriological testing and tests for antibiotic synergism are necessary.
Enzymatic inactivation of deoxystreptamine is the principal mechanism of resistance.
Susceptibility Testing
Quantitative methods for susceptibility testing that require measurement of zone diameters give the most precise estimates of antibiotic susceptibility.  One such procedure has been recommended for use with discs to test susceptibility to kanamycin.  Interpretation involves correlation of the diameters obtained in the disc test with minimal inhibitory concentration (MIC) values for kanamycin.
Reports from the laboratory give results of the standardized single disc susceptibility test (Bauer, et al., Am J Clin Path 1966;45:493 and Federal Register 37:20525-20529, 1972), using a 30 mcg kanamycin disc should be interpreted according to the following criteria:
Organisms producing zones of 18 mm or greater, or MIC’s of 16 mcg or less are considered susceptible, indicating that the test organism is likely to respond to therapy.
Resistant organisms produce zones of 14 mm or less or MIC’s of 16 mcg or greater.  A report of “resistant” from the laboratory indicates that the infecting organism is not likely to respond to therapy.
Zones greater than 14 mm and less than 18 mm, or MIC’s of greater than 16 mcg and less than 65 mcg, indicate intermediate susceptibility.  A report of “intermediate” susceptibility suggests that the organism would be susceptible if the infection is confined to tissues and fluids (e.g., urine), in which high antibiotic levels are attained.
Control organisms are recommended for susceptibility testing.  Each time the test is performed one or more of the following organisms should be included: Escherichia coli ATCC 15922, Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 27853.  The control organisms should produce zones of inhibition within the following ranges:

Escherichia coli (ATCC 15922)	22-30 mm
Staphylococcus aureus (ATCC 25923)	22-31 mm
Pseudomonas aeruginosa (ATCC 27853)	17-23 mm

INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Kanamycin Injection and other antibacterial drugs, Kanamycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Kanamycin injection is indicated in the shortterm treatment of serious infections caused by susceptible strains of the designated microorganisms below.  Bacteriological studies to identify the causative organisms and to determine their susceptibility to kanamycin should be performed.  Therapy may be instituted prior to obtaining the results of susceptibility testing.
Kanamycin may be considered as initial therapy in the treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species.  The decision to continue therapy with the drug should be based on results of the susceptibility tests, the response of the infection to therapy, and the important additional concepts contained in the WARNING box above.
In serious infections when the causative organisms are unknown, kanamycin injection, may be administered as initial therapy in conjunction with a penicillin- or cephalosporin-type drug before obtaining results of susceptibility testing.  If anaerobic organisms are suspected, consideration should be given to using other suitable antimicrobial therapy in conjunction with kanamycin.
Although kanamycin is not the drug of choice for staphylococcal infections, it may be indicated under certain conditions for the treatment of known or suspected staphylococcal disease.  These situations include the initial therapy of severe infections where the organism is thought to be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and mixed staphylococcal/Gram-negative infections.
CONTRAINDICATIONS
A history of hypersensitivity or toxic reaction to one aminoglycoside may also contraindicate the use of any other aminoglycoside, because of the known cross-sensitivity and cumulative effects of drugs in this category.
THIS DRUG IS NOT INDICATED IN LONG-TERM THERAPY (e.g., Tuberculosis) BECAUSE OF THE TOXIC HAZARD ASSOCIATED WITH EXTENDED ADMINISTRATION.
WARNINGS
See WARNING box above.
Aminoglycosides can cause fetal harm when administered to pregnant women.  Aminoglycoside antibiotics cross the placenta and there have been several reports of total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy.  Although serious side effects to fetus or newborn have not been reported in treatment of pregnant women with other aminoglycosides, the potential for harm exists.
Reproductive studies have been performed in rats and rabbits and have revealed no evidence of impaired fertility or teratogenic effects.  Dosages of 200 mg/kg/day in pregnant rats and pregnant guinea pigs led to hearing impairment in the off-spring.  There are no well-controlled studies in pregnant women but clinical experience does not include any positive evidence of adverse effects on the fetus.  However, if the drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard on the fetus.
Contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS
GeneralPrescribing Kanamycin Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Neurotoxic and nephrotoxic antibiotics may be almost completely absorbed from body surfaces (except the urinary bladder) after local irrigation and after topical application during surgical procedures.  The potential toxic effects of antibiotics administered in this fashion (otoand nephrotoxicity, neuromuscular blockade, respiratory paralysis) should be considered (see WARNING box).
Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and with some cephalosporins.
Aminoglycosides should be used with caution in patients with neuromuscular disorders such as myasthenia gravis, Parkinsonism, or infant botulism, since these drugs may aggravate muscle weakness because of their potential curare-like effect on neuromuscular function.
Elderly patients may have a decrease in renal function which may not be evident in the results of routine screening tests, such as BUN or serum creatinine levels.  Measurement of creatinine clearance or an estimate based on published nomograms or equations may be more useful.  Monitoring of renal function during treatment with kanamycin, as with other aminoglycosides, is particularly important in such patients.
Because of high concentrations of kanamycin in the urinary excretory system, patients should be well hydrated before treatment to prevent irritation of the renal tubules.
NOTE: The risk of toxic reactions is low in well-hydrated patients with normal Kidney function, who receive a total dose of 15 g of kanamycin or less.
Treatment with kanamycin may result in overgrowth of nonsusceptible organisms.  If this occurs kanamycin should be discontinued and appropriate therapy initiated.
Information for Patients
Patients should be counseled that antibacterial drugs including Kanamycin Injection should only be used to treat bacterial infections.  They do not treat viral infections (e.g., the common cold).  When Kanamycin Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Kanamycin Injection or other antibacterial drugs in the future.
Laboratory Tests
Tests of eighth cranial nerve functions: Serial audiometric tests are suggested, particularly when renal function is impaired and/or prolonged aminoglycoside therapy is required; such tests should also be repeated periodically after treatment if there is evidence of a hearing deficit or vestibular abnormalities before or during therapy, or when consecutive or concomitant use of other potentially ototoxic drug is unavoidable.
Test of renal function: It should be emphasized that since renal function may alter appreciably during therapy, renal function should be tested daily or more frequently.  Urine should be examined for increased excretion of protein and for presence of cells and casts, keeping in mind the effects of the primary illness on these tests.  One or more of the following laboratory measurements should be obtained at the onset of therapy, frequently during therapy, and at, or shortly after, the end of therapy:
    Creatinine clearance rate (either carefully measured or estimated from published nomograms or equations based on patient’s age, sex, body weight, and serial creatinine concentrations) (preferred over BUN).
    Serum creatinine concentration (preferred over BUN).
    Blood urea nitrogen (BUN).
More frequent testing is desirable if renal function is changing.  If signs of renal irritation appear, such as casts, white or red cells, and albumin, hydration should be increased and a reduction in dosage may be desirable (see DOSAGE AND ADMINISTRATION).  These signs usually disappear when treatment is completed.  However, if azotemia or a progressive decrease of urine output occurs, treatment should be stopped.
Drug Interactions
In vitro mixing of an aminoglycoside with beta-lactam-type antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.  Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.  Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function (see also Laboratory Test Interactions).  See WARNING box regarding concurrent use of potent diuretics, concurrent and/or sequential use of other neurotoxic and/or nephrotoxic antibiotics, and for other essential information.
Laboratory Test Interactions
Concomitant cephalosporin therapy may spuriously elevate creatinine determinations.
The inactivation between aminoglycosides and beta-lactam antibiotics described in Drug Interactions may continue in specimens of body fluids collected for assay, resulting in inaccurate, false low aminoglycoside readings.  Such specimens should be properly handled, i.e., assayed promptly, frozen, or treated with beta-lactamase.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies have not been performed with kanamycin to determine its effect in carcinogenesis, mutagenesis, or impairment of fertility.
Pregnancy Category D
(See WARNINGS section).
Nursing Mothers
Kanamycin is excreted in minute amounts in human milk.  Because of the potential for serious adverse reactions from aminoglycosides in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.
Pediatric Use
Aminoglycosides should be used with caution in prematures and neonates because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.
ADVERSE REACTIONS
Kanamycin has the potential to induce auditory and sometimes vestibular toxicity, renal toxicity, and neuromuscular blockade.  The risks are higher for patients with a present or past history of renal impairment (especially if hemodialysis is required): for those receiving concomitant or sequential treatment with other ototoxic or nephrotoxic drugs or rapid acting diuretic agents given intravenously (ethacrynic acid, furosemide, and mannitol), and for patients treated for longer periods and/or with higher doses than recommended.
OtotoxicityToxic effects of kanamycin on the eighth cranial nerve can result in partially reversible or irreversible bilateral loss of hearing, loss of balance, or both.  Tinnitus or vertigo may or may not be experienced.  Cochlear damage is usually manifested initially by small changes in audiometric test results at the high frequencies and may not be associated with subjective hearing loss.  Vestibular dysfunction is usually manifested by nystagmus, vertigo, nausea, vomiting, or acute Meniere’s syndrome.
NephrotoxicityAlbuminuria, presence of red and white cells, and granular casts; azotemia and oliguria have been reported.  Renal function changes are usually reversible when the drug is discontinued.  Renal impairment may be characterized by a rise in serum creatinine and may be accompanied by oliguria, presence of casts, cells, and protein in the urine, by rising levels of BUN or by decrease in creatinine clearance.
Neuromuscular Blockage
Acute muscular paralysis and apnea can occur following treatment with aminoglycoside antibiotics.  Neurotoxicity can occur after intrapleural and interperitoneal instillation of large doses of an aminoglycoside; however, the reaction has followed intravenous, intramuscular, and even the oral administration of these agents.
OtherSome local irritation or pain may follow the intramuscular injection of kanamycin.  Other adverse reactions of the drug reported on rare occasions are skin rash, drug fever, headache, paresthesia, nausea, vomiting, and diarrhea.  The “malabsorption syndrome” characterized by an increase in fecal fat, decrease in serum carotene, and fall in xylose absorption, reportedly has occurred with prolonged therapy.
OVERDOSAGE
In the event of overdosage or toxic reaction, hemodialysis or peritoneal dialysis will aid in the removal of kanamycin from the blood.  In the newborn infant, exchange transfusion may also be considered.
DOSAGE AND ADMINISTRATION
Kanamycin injection may be given intramuscularly or intravenously.  The patient’s pretreatment body weight should be obtained for calculation of the correct dosage.  The dosage of an aminoglycoside in obese patients should be based on an estimate of the lean body mass.  The status of renal function should be determined by measurement of serum creatinine concentration or calculation of the endogenous creatinine clearance rate.  The blood urea nitrogen (BUN) level is much less reliable for this purpose.  Renal function should be reassessed frequently during therapy.
It is desirable to measure both peak and trough serum concentrations intermittently during therapy since both concentrations are used to determine the adequacy and safety of the dose and to adjust the dosage during treatment.  Peak serum concentrations (30 to 90 minutes after injection) above 35 mcg per mL and trough concentrations (just prior to the next dose) above 10 mcg per mL should be avoided.
Intramuscular Route
Inject deeply into the upper outer quadrant of the gluteal muscle.  The recommended dose for adults or children is 15 mg/kg/day in two equally divided dosages administered at equally divided intervals; i.e., 7.5 mg/kg q12h.  If continuously high blood levels are desired, the daily dose of 15 mg/kg may be given in equally divided doses every 6 or 8 hours.  Treatment of patients in the heavier weight classes, i.e., 100 kg, should not exceed 1.5 g/day.
In patients with impaired renal function, it is desirable to follow therapy by appropriate serum assays.  If this is not feasible, a suggested method is to reduce the frequency of administration in patients with renal dysfunction.  The interval between doses may be calculated with the following formula:
Serum creatinine (mg/100 mL) x 9 = Dosage Interval (in hours); e.g., if the serum creatinine is 2 mg, the recommended dose (7.5 mg/kg) should be administered every 18 hours.  Changes in creatinine concentration during therapy would, of course, necessitate changes in the dosage frequency.
It is desirable to limit the duration of treatment with kanamycin to short-term.  The usual duration of treatment is 7 to 10 days.  Total daily dose by all routes of administration should not exceed 1.5 g/day.  If longer therapy is required, measurement of kanamycin peak and trough serum concentrations is particularly important as a basis for determining the adequacy and safety of the dose.  These patients should be carefully monitored for changes in renal, auditory, and vestibular function.  Dosage should be adjusted as needed.  The risks of toxicity multiply as the length of treatment increases.
At the recommended dosage level, uncomplicated infections due to kanamycin-susceptible organisms should respond to therapy in 24 to 48 hours.  If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked.  Failure of the infection to respond may be due to resistance of the organism or to the presence of septic foci requiring surgical drainage.
Intravenous Administration
The dose should not exceed 15 mg/kg per day and must be administered slowly.  The solution for intravenous use is prepared by adding the contents of a 500 mg vial to 100 to 200 mL of sterile diluent such as Normal Saline or 5% Dextrose in Water, or the contents of a 1g vial to 200 to 400 mL of sterile diluent.  The appropriate dose is administered over a 30- to 60-minute period.  The total daily dose should be divided into 2 or 3 equally divided doses.
Kanamycin Injection, USP should not be physically mixed with other antibacterial agents but each should be administered separately in accordance with its recommended route of administration and dosage schedule.
Intraperitoneal Use
(Following exploration for established peritonitis or after peritoneal contamination due to fecal spill during surgery.)
Adults500 mg diluted in 20 mL sterile distilled water may be instilled through a polyethylene catheter sutured into the wound at closure.  If possible, instillation should be postponed until the patient has fully recovered from the effects of anesthesia and muscle-relaxing drugs (see duration of treatment statement above and WARNING box).  Serum levels should be carefully monitored during treatment.
NOTE: The pediatric dosage form “75 mg/2 mL” should be used for pediatric patients.
Aerosol Treatment
250 mg two to four times a day.  Withdraw 250 mg (1mL) from a 500 mg vial and dilute it with 3 mL Physiological Saline and nebulize.  Serum levels should be carefully monitored during treatment.
Other Routes of Administration
Kanamycin injection in concentrations of 0.25 percent (2.5 mg/mL) has been used as an irrigating solution in abscess cavities, pleural space, peritoneal and ventricular cavities.  Possible absorption of kanamycin by such routes must be taken into account and dosage adjustments should be arranged so that a maximum total dose of 1.5 g/day by all routes of administration is not exceeded.  Serum levels should be carefully monitored during treatment.
STABILITY
Occasionally, some vials may darken during the shelf life of the product, but this does not indicate a loss of potency.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever container and solution permit.
HOW SUPPLIED

Product No.	NDC No.	Strength	Vial Size
305802	63323-358-02	500 mg/vial	2 mL fill in a 3 mL vial.
305903	63323-359-03	1 gram/vial	3 mL fill in a 5 mL vial.

Kanamycin Injection, USP, is supplied in packages of 10 vials.
Vial stoppers do not contain natural rubber latex.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].